E. Donnall Thomas and the First Bone Marrow Transplants

Long before laboratory dishes held embryonic or induced pluripotent stem cells, physicians were already moving blood-forming cells from one person to another. The clinical path to what we now call hematopoietic stem cell transplantation runs through mid-century radiation biology, failed early grafts, identical-twin experiments, tissue typing, and decades of work led most prominently by E. Donnall Thomas.

Early attempts and the 1957 NEJM report

By the mid-1950s, mouse studies had shown that marrow cells could rescue animals after otherwise lethal radiation. Thomas, working with Joseph Ferrebee at the Mary Imogene Bassett Hospital in Cooperstown, New York, began cautious human trials. In 1957 they reported in the New England Journal of Medicine on intravenous infusion of marrow in six patients. The paper showed that large amounts of properly prepared marrow could be given safely. It also showed how hard allogeneic grafting would be: only one patient had a transient graft, and lasting success was not achieved.

Those results were not unique. Across the late 1950s and early 1960s, many allogeneic marrow attempts worldwide failed. Without a way to match donors and recipients, grafts were rejected or caused fatal graft-versus-host disease. Thomas later wrote that allogeneic marrow grafting in humans looked very difficult indeed.

Identical twins: proof that marrow can engraft

Progress came first in a genetically matched setting. In 1959, Thomas and colleagues reported marrow transplants between identical twins after high-dose total body irradiation for refractory leukemia. The twin marrow restored blood counts and showed that an intravenous marrow infusion could protect against lethal irradiation. The leukemia still returned within months, which pushed the field to ask what else—immune effects, better disease control, or better timing—would be needed for cure.

Those syngeneic cases mattered. They separated the mechanical and engraftment questions from the histocompatibility problem. Marrow could work. Matching was the next barrier.

Dogs, HLA, and the 1968 breakthroughs

Thomas’s team turned heavily to dogs, an outbred model closer to human diversity than inbred mice. Canine studies clarified radiation doses, cryopreservation, peripheral-blood cell infusions, and the severity of graft-versus-host disease. Rare long-term survivors among matched littermates treated with methotrexate hinted that donor selection was decisive.

Human leukocyte antigen (HLA) typing then changed clinical practice. In 1968, two groups reported successful HLA-identical sibling marrow transplants for primary immunodeficiency: Robert A. Good’s team in Minnesota and Fritz H. Bach’s team in Wisconsin. Those cases showed that, with tissue matching, donor marrow could rebuild a working blood and immune system in humans. Thomas’s program incorporated HLA matching as clinical transplantation expanded.

Seattle and the Fred Hutchinson Cancer Research Center

In 1963 Thomas moved to Seattle at the University of Washington’s invitation and built his program at the Seattle Public Health Hospital. After a temporary period at Providence Hospital when the Public Health Hospital faced closure, the team moved in 1975 into the Fred Hutchinson Cancer Research Center, working with Swedish Hospital Medical Center. There the group combined laboratory work, critical-care nursing teams, and a growing series of transplants for leukemia, aplastic anemia, and genetic blood diseases.

Outcomes improved as conditioning, infection control, HLA matching, and graft-versus-host disease management advanced. The Seattle program became a major training and referral center. The same clinical tradition sits on this site’s timeline beside earlier bone marrow milestones and later regulatory and cell-therapy events.

The 1990 Nobel Prize

In 1990 the Nobel Prize in Physiology or Medicine was awarded jointly to Joseph E. Murray and E. Donnall Thomas for discoveries concerning organ and cell transplantation in the treatment of human disease. Murray’s work centered on kidney transplantation; Thomas’s on bone marrow transplantation. The Nobel Assembly credited marrow grafting as a route to cure severe inherited disorders, immune deficiencies, leukemia, and aplastic anemia.

Thomas remained associated with Fred Hutch and later spoke in favor of carefully overseen stem cell research. He died on October 20, 2012.

Thomas’s Nobel lecture and later biographical accounts stress continuity: dog immunology, irradiation biology, nursing teams capable of prolonged critical care, and incremental gains against infection and graft-versus-host disease. The work was never a single dramatic operation. It was a program that stayed with a hard problem after many groups left the field.

Today’s transplant centers still measure success with the same basic endpoints—engraftment, relapse, infection, and graft-versus-host disease—even as graft sources diversified to include cord blood and mobilized peripheral blood stem cells. Regulatory categories such as HCT/Ps and later cellular therapies sit downstream of that clinical infrastructure.

Why it matters today

Modern hematopoietic stem cell transplants—from bone marrow, mobilized peripheral blood, or umbilical cord blood—still rest on the problems Thomas’s generation faced: conditioning, engraftment, infection, graft-versus-host disease, and donor matching. Related vocabulary on this site includes autologous and allogeneic grafts, HLA matching, engraftment, and GVHD. The clinical field also overlaps later debates about embryonic stem cells and induced pluripotent stem cells, covered in posts such as Till and McCulloch’s 1961 proof and what iPS cells changed.

Bone marrow transplantation did not begin as a “stem cell brand.” It began as an attempt to replace a destroyed blood-forming system. That practical goal remains the clearest through-line from Cooperstown and Seattle to today’s transplant wards.

Sources

• E. Donnall Thomas – Biographical, NobelPrize.org
• Nobel Prize in Physiology or Medicine 1990 press release
• E. Donnall Thomas Nobel Lecture (PDF)
• Thomas E.D., Lochte H.L. Jr, Lu W.C., Ferrebee J.W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957.
• Thomas E.D., Lochte H.L. Jr, Cannon J.H., Sahler O.D., Ferrebee J.W. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest. 1959.
• Historical review of bone marrow transplantation for immunodeficiencies (1968 Good and Bach cases)

This article is educational history only. It is not medical advice and does not recommend treatments.